12
Participants
Start Date
April 30, 2012
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2017
Dovitinib
Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
Aromatase Inhibitors
Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Georgetown University
OTHER